Literature DB >> 29451820

The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.

Dan F Smelter1, Willem J de Lange1, Wenxuan Cai2,3, Ying Ge2,4,5, J Carter Ralphe1.   

Abstract

Cardiac myosin-binding protein C (cMyBP-C) is a functional sarcomeric protein that regulates contractility in response to contractile demand, and many mutations in cMyBP-C lead to hypertrophic cardiomyopathy (HCM). To gain insight into the effects of disease-causing cMyBP-C missense mutations on contractile function, we expressed the pathogenic W792R mutation (substitution of a highly conserved tryptophan residue by an arginine residue at position 792) in mouse cardiomyocytes lacking endogenous cMyBP-C and studied the functional effects using three-dimensional engineered cardiac tissue constructs (mECTs). Based on complete conservation of tryptophan at this location in fibronectin type II (FnIII) domains, we hypothesized that the W792R mutation affects folding of the C6 FnIII domain, destabilizing the mutant protein. Adenoviral transduction of wild-type (WT) and W792R cDNA achieved equivalent mRNA transcript abundance, but not equivalent protein levels, with W792R compared with WT controls. mECTs expressing W792R demonstrated abnormal contractile kinetics compared with WT mECTs that were nearly identical to cMyBP-C-deficient mECTs. We studied whether common pathways of protein degradation were responsible for the rapid degradation of W792R cMyBP-C. Inhibition of both ubiquitin-proteasome and lysosomal degradation pathways failed to increase full-length mutant protein abundance to WT equivalence, suggesting rapid cytosolic degradation. Bacterial expression of WT and W792R protein fragments demonstrated decreased mutant stability with altered thermal denaturation and increased susceptibility to trypsin digestion. These data suggest that the W792R mutation destabilizes the C6 FnIII domain of cMyBP-C, resulting in decreased full-length protein expression. This study highlights the vulnerability of FnIII-like domains to mutations that alter domain stability and further indicates that missense mutations in cMyBP-C can cause disease through a mechanism of haploinsufficiency. NEW & NOTEWORTHY This study is one of the first to describe a disease mechanism for a missense mutation in cardiac myosin-binding protein C linked to hypertrophic cardiomyopathy. The mutation decreases stability of the fibronectin type III domain and results in substantially reduced mutant protein expression dissonant to transcript abundance.

Entities:  

Keywords:  cardiac myosin-binding protein C; fibronectin type III; hypertrophic cardiomyopathy; missense mutation

Mesh:

Substances:

Year:  2018        PMID: 29451820      PMCID: PMC6032085          DOI: 10.1152/ajpheart.00686.2017

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  38 in total

1.  MASH Suite Pro: A Comprehensive Software Tool for Top-Down Proteomics.

Authors:  Wenxuan Cai; Huseyin Guner; Zachery R Gregorich; Albert J Chen; Serife Ayaz-Guner; Ying Peng; Santosh G Valeja; Xiaowen Liu; Ying Ge
Journal:  Mol Cell Proteomics       Date:  2015-11-23       Impact factor: 5.911

2.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.

Authors:  Antonio Sarikas; Lucie Carrier; Carolus Schenke; Daniela Doll; Jeanne Flavigny; Katrin S Lindenberg; Thomas Eschenhagen; Oliver Zolk
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

3.  Thermofluor-based high-throughput stability optimization of proteins for structural studies.

Authors:  Ulrika B Ericsson; B Martin Hallberg; George T Detitta; Niek Dekker; Pär Nordlund
Journal:  Anal Biochem       Date:  2006-08-10       Impact factor: 3.365

4.  Structure-critical distribution of aromatic residues in the fibronectin type III protein family.

Authors:  Ema Hoxha; Stephen R Campion
Journal:  Protein J       Date:  2014-04       Impact factor: 2.371

5.  Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice.

Authors:  Samantha P Harris; Christopher R Bartley; Timothy A Hacker; Kerry S McDonald; Pamela S Douglas; Marion L Greaser; Patricia A Powers; Richard L Moss
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

6.  A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.

Authors:  Diederik W D Kuster; Suresh Govindan; Tzvia I Springer; Jody L Martin; Natosha L Finley; Sakthivel Sadayappan
Journal:  J Biol Chem       Date:  2015-01-12       Impact factor: 5.157

Review 7.  The 20 advances that have defined contemporary hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron
Journal:  Trends Cardiovasc Med       Date:  2015-01       Impact factor: 6.677

8.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Vlad C Vasile; Steve R Ommen; Melissa L Will; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

9.  The degradation pathway for the HBV envelope proteins involves proteolysis prior to degradation via the cytosolic proteasome.

Authors:  Yuanjie Liu; Tianlun Zhou; Ender Simsek; Timothy Block; Anand Mehta
Journal:  Virology       Date:  2007-08-23       Impact factor: 3.616

10.  High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering.

Authors:  Jason J Lavinder; Sanjay B Hari; Brandon J Sullivan; Thomas J Magliery
Journal:  J Am Chem Soc       Date:  2009-03-25       Impact factor: 15.419

View more
  5 in total

1.  Human iPSC-engineered cardiac tissue platform faithfully models important cardiac physiology.

Authors:  Willem J de Lange; Emily T Farrell; Caroline R Kreitzer; Derek R Jacobs; Di Lang; Alexey V Glukhov; J Carter Ralphe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-02-19       Impact factor: 4.733

2.  The distal arthrogryposis-linked p.R63C variant promotes the stability and nuclear accumulation of TNNT3.

Authors:  Jinfang Lu; Huanzheng Li; He Zhang; Zhengxiu Lin; Chenyang Xu; Xueqin Xu; Lin Hu; Zhaotang Luan; Yongliang Lou; Shaohua Tang
Journal:  J Clin Lab Anal       Date:  2021-11-11       Impact factor: 2.352

3.  Assessment of the Contribution of a Thermodynamic and Mechanical Destabilization of Myosin-Binding Protein C Domain C2 to the Pathomechanism of Hypertrophic Cardiomyopathy-Causing Double Mutation MYBPC3Δ25bp/D389V.

Authors:  Frederic V Schwäbe; Emanuel K Peter; Manuel H Taft; Dietmar J Manstein
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

4.  Functionally Integrated Top-Down Proteomics for Standardized Assessment of Human Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissues.

Authors:  Jake A Melby; Willem J de Lange; Jianhua Zhang; David S Roberts; Stanford D Mitchell; Trisha Tucholski; Gina Kim; Andreas Kyrvasilis; Sean J McIlwain; Timothy J Kamp; J Carter Ralphe; Ying Ge
Journal:  J Proteome Res       Date:  2021-01-04       Impact factor: 4.466

5.  Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy.

Authors:  Carmen Suay-Corredera; Maria Rosaria Pricolo; Diana Velázquez-Carreras; Divya Pathak; Neha Nandwani; Carolina Pimenta-Lopes; David Sánchez-Ortiz; Iñigo Urrutia-Irazabal; Silvia Vilches; Fernando Dominguez; Giulia Frisso; Lorenzo Monserrat; Pablo García-Pavía; David de Sancho; James A Spudich; Kathleen M Ruppel; Elías Herrero-Galán; Jorge Alegre-Cebollada
Journal:  ACS Nano       Date:  2021-06-01       Impact factor: 18.027

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.